Pharmaceutical Company Discloses Why It Stopped Trials of New Vaccine

Published on March 14, 2024

The pharmaceutical giant GlaxoSmithKline (GSK) abandoned a maternal vaccine because there was an unexplained higher incidence of preterm birth among infants whose mothers received the shot, the company disclosed in a new study. Among women who received GSK’s respiratory syncytial virus (RSV) vaccine, known as RSVPreF3-Mat, during pregnancy, 237 had infants born prematurely. Just 89 in the placebo group suffered the same problem. Percentage-wise, 6.8 percent of the vaccinated women had infants born prematurely, compared to 4.9 percent of women who received a placebo, researchers reported in the New England Journal of Medicine. “For every 54 infants born to women who received RSVPreF3-Mat rather than placebo during pregnancy, one additional preterm birth occurred,” the researchers said....